Mavoglurant(Mavoglurant) - 药物靶点：mGluR5_在研适应症：物质滥用，戒酒，酒精使用障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

mGluR5

作用机制

mGluR5 负变构调节剂(代谢型谷氨酸受体-5 负变构调节剂)

治疗领域

其他疾病肿瘤神经系统疾病

在研适应症

物质滥用戒酒酒精使用障碍+ [5]

非在研适应症

药物性运动障碍运动失调脆性X综合征+ [7]

原研机构

Novartis Pharma AG

在研机构

Novartis AG

National Institute on Alcohol Abuse & Alcoholism

Stalicla SA初创企业

+ [1]

非在研机构

Novartis Pharmaceuticals Corp.

Novartis Pharmaceuticals Canada, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C19H23NO3

InChIKeyZFPZEYHRWGMJCV-ZHALLVOQSA-N

CAS号543906-09-8

关联

32

项与 Mavoglurant 相关的临床试验

NCT06136195

/ Recruiting临床2期IIT

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.

开始日期2024-07-01

申办/合作机构

Yale University

[+1]

NCT06273540

/ Completed临床1期

Phase 1, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral STP7

This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v. cocaine's physiological and subjective effects in non-treatment seeking, cocaine-experienced males or females participants between 18 and 59 years of age.
The primary objective of this study is to determine if there are clinically meaningful interactions between oral STP7 (mavoglurant) treatment concurrent with 20 and 40 mg i.v. cocaine infusions by measuring adverse events and cardiovascular responses including heart rate, blood pressure, and electrocardiogram (including corrected QT interval).
The secondary objectives are:
* To evaluate whether administration of STP7 (mavoglurant) alters the pharmacokinetics of cocaine and/or its major metabolite, benzoylecgonine.
* To determine the pharmacokinetic of STP7 (mavoglurant) administered at a dose of 200 mg twice a day.
* To evaluate whether STP7 (mavoglurant) treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS) and Brief Substance Craving Scale (BSCS).

开始日期2024-04-15

申办/合作机构

Stalicla SA初创企业

[+1]

NCT05203965

/ Recruiting早期临床1期IIT

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.

开始日期2022-05-17

申办/合作机构

Yale University

[+1]

100 项与 Mavoglurant 相关的临床结果

登录后查看更多信息

100 项与 Mavoglurant 相关的转化医学

登录后查看更多信息

100 项与 Mavoglurant 相关的专利（医药）

登录后查看更多信息

63

项与 Mavoglurant 相关的文献（医药）

2024-11-01·Psychopharmacology

The mGlu5 receptor negative allosteric modulator mavoglurant reduces escalated cocaine self-administration in male and female rats

Article

作者: Whiting, Kimberly E ; Volkow, Nora D ; Vendruscolo, Janaina C M ; Vendruscolo, Leandro F ; Acri, Jane B ; Koob, George F

AbstractRationaleCocaine use disorder (CUD) is a brain disorder for which there is no Food and Drug Administration-approved pharmacological treatment. Evidence suggests that glutamate and metabotropic glutamate receptor subtype 5 (mGlu5) play critical roles in synaptic plasticity, neuronal development, and psychiatric disorders.ObjectiveIn the present study, we tested the hypothesis that the mGlu5 receptor is functionally involved in intravenous cocaine self-administration and assessed the effects of sex and cocaine exposure history.MethodsWe used a preclinical model of CUD in rats that were allowed long access (LgA; 6 h/day) or short access (ShA; 1 h/day) to intravenous cocaine (750 µg/kg/infusion [0.1 ml]) self-administration. Rats received acute intraperitoneal or oral administration of the mGlu5 receptor negative allosteric modulator mavoglurant (1, 3, and 10 mg/kg) or vehicle.ResultsBoth intraperitoneal and oral mavoglurant administration dose-dependently reduced intravenous cocaine self-administration in the first hour and in the entire 6 h session in rats in the LgA group, with no effect on locomotion. In the ShA group, mavoglurant decreased locomotion but had no effects on cocaine self-administration. We did not observe significant sex × treatment interactions.ConclusionsThese findings suggest that the mGlu5 receptor is involved in escalated cocaine self-administration. These findings support the development of clinical trials of mavoglurant to evaluate its potential therapeutic benefits for CUD.

2024-03-01·Journal of Clinical Investigation

Effects of AFQ056 on language learning in fragile X syndrome

Article

作者: Kaufmann, Walter E ; Cudkowicz, Merit ; Klingner, Elizabeth ; Long, Jeff ; Huff, Trevis ; McDuffie, Andrea ; Erickson, Craig A ; Costigan, Michele ; Friedmann, Katherine ; Berry-Kravis, Elizabeth ; Moshinsky, Michael ; Fedler, Janel ; Harkey, Brittney ; Hagerman, Randi ; Tassone, Flora ; Hoffmann, Anne ; Pearson, Brenda ; Veenstra-VanderWeele, Jeremy ; Ecklund, Dixie ; Bullard, Lauren ; Staley, Kevin ; Coffey, Christopher S ; Klements, David ; Hessl, David ; Ethridge, Lauren ; Abbeduto, Leonard

BACKGROUNDFXLEARN, the first-ever large multisite trial of effects of disease-targeted pharmacotherapy on learning, was designed to explore a paradigm for measuring effects of mechanism-targeted treatment in fragile X syndrome (FXS). In FXLEARN, the effects of metabotropic glutamate receptor type 5 (mGluR5) negative allosteric modulator (NAM) AFQ056 on language learning were evaluated in 3- to 6-year-old children with FXS, expected to have more learning plasticity than adults, for whom prior trials of mGluR5 NAMs have failed.METHODSAfter a 4-month single-blind placebo lead-in, participants were randomized 1:1 to AFQ056 or placebo, with 2 months of dose optimization to the maximum tolerated dose, then 6 months of treatment during which a language-learning intervention was implemented for both groups. The primary outcome was a centrally scored videotaped communication measure, the Weighted Communication Scale (WCS). Secondary outcomes were objective performance-based and parent-reported cognitive and language measures.RESULTSFXLEARN enrolled 110 participants, randomized 99, and had 91 who completed the placebo-controlled period. Although both groups made language progress and there were no safety issues, the change in WCS score during the placebo-controlled period was not significantly different between the AFQ056 and placebo-treated groups, nor were there any significant between-group differences in change in any secondary measures.CONCLUSIONDespite the large body of evidence supporting use of mGluR5 NAMs in animal models of FXS, this study suggests that this mechanism of action does not translate into benefit for the human FXS population and that better strategies are needed to determine which mechanisms will translate from preclinical models to humans in genetic neurodevelopmental disorders.TRIAL REGISTRATIONClincalTrials.gov NCT02920892.FUNDING SOURCESNeuroNEXT network NIH grants U01NS096767, U24NS107200, U24NS107209, U01NS077323, U24NS107183, U24NS107168, U24NS107128, U24NS107199, U24NS107198, U24NS107166, U10NS077368, U01NS077366, U24NS107205, U01NS077179, and U01NS077352; NIH grant P50HD103526; and Novartis IIT grant AFQ056X2201T for provision of AFQ056.

2024-02-01·Heliyon

Constrained numerical deconvolution using orthogonal polynomials

Article

作者: Maestre, J M ; Aarons, L ; Chanfreut, P

In this article, we present an enhanced version of Cutler's deconvolution method to address the limitations of the original algorithm in estimating realistic input and output parameters. Cutler's method, based on orthogonal polynomials, suffers from unconstrained solutions, leading to the lack of realism in the deconvolved signals in some applications. Our proposed approach incorporates constraints using a ridge factor and Lagrangian multipliers in an iterative fashion, maintaining Cutler's iterative projection-based nature. This extension avoids the need for external optimization solvers, making it particularly suitable for applications requiring constraints on inputs and outputs. We demonstrate the effectiveness of the proposed method through two practical applications: the estimation of COVID-19 curves and the study of mavoglurant, an experimental drug. Our results show that the extended method presents a sum of squared residuals in the same order of magnitude of that of the original Cutler's method and other widely known unconstrained deconvolution techniques, but obtains instead physically plausible solutions, correcting the errors introduced by the alternative methods considered, as illustrated in our case studies.

12

项与 Mavoglurant 相关的新闻（医药）

2024-09-19

·GlobeNewswire-Health Care

Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor

Press Release Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor Geneva, Switzerland – September 19, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental disorders, announced today that Dr. Paulo Fontoura will be joining their drug development team as Chief Scientific and Clinical Development Advisor. Dr. Fontoura will work to support STALICLA’s mission to transform the treatment landscape for neurodevelopmental disorders. Lynn Durham, CEO of STALICLA, said: “We are delighted and humbled to welcome Paulo to the STALICLA team. With his unparalleled insight and unique understanding of CNS drug development and neurodevelopmental disorders, he is strengthening STALICLA’s position as a pioneer in precision neuropsychiatry. Paulo’s expertise will be instrumental in helping us achieve our next milestones, notably our entry into two Phase 2 clinical trials in subgroups of patients with autism spectrum disorder (ASD), each with expected readouts in the coming 24 months.” Dr. Paulo Fontoura is a pioneer in innovative clinical development strategies. During his 16-year tenure at Roche, he served as the Global Head of Neuroscience Clinical Development; he was instrumental in the launch of several groundbreaking medications targeting neurological conditions, including Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), and Neuromyelitis Optica Spectrum Disorder (NMOSD), as well as pioneering work on Alzheimer's, Parkinson's, Huntington's disease, and several psychiatric and neurodevelopmental disorders. Specifically, he and his team spearheaded the clinical development of new therapies for Fragile X, Down's and Angelman's syndromes, and the first pharmacological treatment for core symptoms of ASD which reached Phase 3 clinical trials in both adults and children. Additionally, his team co-led the Autism Innovative Medicine Studies (AIMS) including EU-AIMS and AIMS-2-TRIALS public private partnership. Dr. Fontoura has also had an illustrious academic career. He held multiple faculty positions at the New University of Lisbon and Stanford University, where he earned his MD and a PhD in Neuroimmunology and trained as a clinical neurologist. In recognition of his exceptional achievements in the field of neuroscience, he was elected as a Fellow of the American Academy of Neurology in 2022. He currently serves as a visiting professor at the New University of Lisbon and lectures at the European Center of Pharmaceutical Medicine in Basel. Paulo Fontoura MD, PhD, Chief Scientific and Clinical Development Advisor, said: “I am thrilled to join the STALICLA team and help them develop therapies for people with neurodevelopmental disorders. Their approach promises to bring real breakthroughs in this area of great medical need.” About STALICLA: STALICLA SA is a Swiss clinical-stage biopharmaceutical company, revolutionizing the treatment of neurodevelopmental disorders. The company has developed a clinically validated neuro precision development platform, successfully delivering stratified patient subgroups and advancing tailored treatment options. Its lead NDD asset, STP1, and a second NDD asset are set to enter Phase 2 trials with expected readouts within 24 months. STP7 (Mavoglurant), is also being advanced for Phase 3 trials, fully funded by the US government. For more information, please visit: www.stalicla.com. Contacts: STALICLA SALynn Durham Founder & Chief Executive Officerlynn.durham@stalicla.com Media & InvestorsChris MaggosCohesion Bureauchris.maggos@cohesionbureau.com+41 79 367 6254 Attachment 20240918 Paulo Fontoura PR_final

临床2期临床3期高管变更

2024-06-28

·GlobeNewswire-Health Care

STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines

STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core symptoms June 27, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neuropsychiatric and neurodevelopmental disorders, today announced the publication of a landmark phase 1b study with STP1, a novel combination therapy tailored for the treatment of a clinically and biologically defined subgroup of patients with autism spectrum disorder (ASD), named ASD Phenotype 1 (ASD-Phen1). The results of the study were published in the peer-reviewed journal Biomedicines, in an article titled “Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD”. Lynn Durham, CEO of STALICLA, highlighted: “This study marks a significant milestone in the advancement of precision medicine for ASD. It is a first-of-its-kind stratification-based approach for clinical development in neurodevelopmental disorders, demonstrating the potential of precision medicine in ASD.” The randomized, double-blind, placebo-controlled phase 1b clinical trial evaluated the safety and tolerability of STP1, a combination of ibudilast and bumetanide, in ASD-Phen1 patients. The clinical trial (registered at clinicaltrials.gov NCT04644003), involved two 14-day treatment phases of ASD-Phen1 patients receiving STP1 or placebo. The results showed that STP1 was well-tolerated with no significant adverse effects reported. Significant and dose-related reductions in gamma power were observed in the whole brains of patients taking STP1, particularly in regions associated with executive function and memory. Additionally, STP1 increased alpha 2 power in frontal and occipital regions, while improving habituation and neural synchronization to auditory chirps. Dr. Craig A. Erickson, Associate Professor, UC Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children’s Hospital Medical Center, and the principal investigator of the study, remarked: “The electrophysiological signals from this study are remarkable and represent the strongest early trial target engagement signals our lab has seen in the autism field.” Dr. Laura Pérez-Cano, Head of Discovery at STALICLA and co-author of the study, added: “These findings not only highlight the potential of STP1 as a therapeutic option for ASD-Phen1 patients but also underscore the importance of combining biologically-based patient stratification with quantifiable outcome measures such as EEG that can then be correlated with behavioral measures.” By focusing on a biologically defined subgroup of ASD patients, STALICLA is moving closer to making personalized treatment options a reality for patients with ASD. This approach has the potential to revolutionize the treatment of ASD and other neuropsychiatric conditions. STALICLA is a global, clinical-stage biotechnology company focused on advancing precision medicine for brain disorders. The company has developed a unique neuro precision development platform, DEPI, supported by clinical validation in a first indication: Autism Spectrum Disorder. Its lead neurodevelopmental disorder asset, STP1, is entering Phase 2 trials. Its lead neuropsychiatry asset, STP7 (Mavoglurant), fully funded by the US government, will soon be Phase 3 ready for Cocaine Use Disorder. ‎ The content above comes from the network. if any infringement, please contact us to modify.

临床结果

2024-05-08

·GlobeNewswire-Health Care

STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder

May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the company's drug-drug interaction (DDI) study of STP7 (Mavoglurant), an mGluR5 negative allosteric modulator, licensed to STALICLA by Novartis. The DDI study is the last regulatory requirement in a comprehensive Phase 2 program and completion is expected to trigger initiation of a Phase 3 study in the U.S. in 2025. Lynn Durham, CEO and Founder of STALICLA said, “This DDI study unlocks the opportunity under our Cooperative Research and Development Agreement with the U.S. NIH National Institute of Drug Abuse (NIDA) to begin Phase 3 trials for STP7 in 2025 to address the high unmet medical need of cocaine abuse globally. Results from successfully completed Phase 2 studies for cocaine use disorder (CUD) showed highly convincing and unprecedented efficacy results including increase in abstinence from cocaine use and reduction in co-morbid dependencies such as alcohol abuse with STP7 (Mavoglurant). In addition, STALICLA is investigating alternative therapeutic indications for STP7 (Mavoglurant) to benefit patients with other CNS conditions.” STP7 (Mavoglurant) is the most clinically advanced negative allosteric modulator of the glutamate receptor 5 (mGluR5 NAM). As well as its role in addiction pathophysiology, mGluR5 has been implicated in mood disorders and neurodevelopmental disorders such as Fragile X and autism spectrum disorder. Comprehensive clinical studies by Novartis of STP7 (Mavoglurant) to date have included over 1800 adults for up to 2 years, demonstrating good safety and tolerability and significant reduction in cocaine use and positioning STP7 (Mavoglurant) as a strong candidate therapy for substance use and other CNS disorders. STALICLA SA is a Swiss clinical-stage biopharmaceutical company, pioneering precision treatment in neurodevelopmental and neuropsychiatric disorders. Its AI-driven precision neuro medicine platform has allowed to identify two precision small molecule drug candidates for autism spectrum disorder, STP1 and STP2, both planned to enter Phase 2 trials in 2024. Following the in-licensing of Mavoglurant from Novartis in 2023, STALICLA has also established an advanced mGluR5 NAM platform offering multi-faceted late-stage clinical development opportunities broadening STALICLA’s scope to address wider CNS disease unmet needs. For more information, please visit: www.stalicla.com. The content above comes from the network. if any infringement, please contact us to modify.

临床3期临床结果

100 项与 Mavoglurant 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Mavoglurant	-	DB13004

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脆性X综合征	临床2期	丹麦	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床2期	意大利	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床2期	澳大利亚	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床2期	荷兰	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床2期	比利时	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床前	荷兰	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床前	比利时	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床前	丹麦	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床前	澳大利亚	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床前	意大利	Novartis Pharmaceuticals Corp.	2011-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03327792 (CTgov)	临床1期	致幻	34	Mavoglurant (200 mg Mavoglurant)	積糧鏇鏇廠簾蓋鬱築鹽(築鏇憲窪夢廠築構簾廠) = 襯襯醖網範糧憲鹽餘獵餘願齋簾鏇襯觸顧艱鹽 (鹹餘願衊築衊製鹹積廠, 願襯構網積觸淵淵構壓 ~ 艱鹽蓋鬱糧艱襯憲齋顧) 更多	-	2024-08-06
				Placebo (Placebo)	積糧鏇鏇廠簾蓋鬱築鹽(築鏇憲窪夢廠築構簾廠) = 醖齋憲鏇夢鬱築獵糧願餘願齋簾鏇襯觸顧艱鹽 (鹹餘願衊築衊製鹹積廠, 蓋廠繭廠製遞顧糧廠衊 ~ 衊壓壓蓋鑰醖製鬱鏇築) 更多
NCT02920892 (FX-LEARN, CTgov)	临床2期	脆性X综合征	110	placebo+AFQ056 (Placebo Comparator: Double-Blind Placebo With Language Intervention)	糧構夢構蓋積窪鏇積膚(範醖糧鹽範窪鬱窪膚齋) = 鬱衊鏇遞淵網鏇襯簾壓範選遞膚製廠鏇鬱鬱壓 (鏇獵艱繭鹽餘製鏇範積, 選壓衊獵範夢夢廠遞衊 ~ 糧鹹壓夢壓積積鏇鹽蓋) 更多	-	2023-10-10
				AFQ056 (Experimental: Double-Blind AFQ056 With Language Intervention)	糧構夢構蓋積窪鏇積膚(範醖糧鹽範窪鬱窪膚齋) = 簾鹹衊築範艱簾膚願願範選遞膚製廠鏇鬱鬱壓 (鏇獵艱繭鹽餘製鏇範積, 襯繭網範築繭齋簾遞鏇 ~ 膚製襯窪蓋構範糧網遞) 更多
NCT03242928 (CTgov)	临床2期	可卡因相关疾病 \| 全身性肉碱缺乏症	68	AFQ056 (AFQ056)	簾築簾艱夢鏇窪艱鹽觸(鏇窪齋艱顧鏇構壓憲繭) = 鏇艱鬱憲憲憲構餘網餘衊遞醖積窪夢願窪夢製 (壓獵蓋鬱鑰鏇夢窪鹹壓, 壓鏇願壓鑰構鏇鹽襯艱 ~ 範範範餘襯壓選壓範艱) 更多	-	2021-02-04
				Placebo (Placebo)	簾築簾艱夢鏇窪艱鹽觸(鏇窪齋艱顧鏇構壓憲繭) = 範夢顧糧積積鬱窪繭醖衊遞醖積窪夢願窪夢製 (壓獵蓋鬱鑰鏇夢窪鹹壓, 顧餘製壓衊顧築壓範餘 ~ 觸糧襯艱鬱繭鬱網鏇構) 更多
WPC2019	N/A	-	485	Mavoglurant (AFQ056)	鬱淵憲簾齋窪窪鹽積齋(選膚選齋鑰壓憲憲簾鏇) = 鬱廠鹽衊蓋窪鏇獵積淵蓋廠遞獵壓廠簾築鹹廠 (窪簾範遞網壓觸範醖遞, -0.65 ~ 0.11) 更多	不佳	2019-06-03
				Placebo	鬱淵憲簾齋窪窪鹽積齋(選膚選齋鑰壓憲憲簾鏇) = 範鑰衊鹽膚壓夢壓衊鏇蓋廠遞獵壓廠簾築鹹廠 (窪簾範遞網壓觸範醖遞, -0.09 ~ 0.66) 更多
NCT01348087 (Pubmed \| Sci Rep) 人工标引	临床2期	脆性X综合征	267	mavoglurant	(築襯蓋廠艱鏇範艱齋淵) = 壓艱遞夢觸夢淵製繭廠選築簾觸範衊餘淵願願 (選繭壓遞夢觸蓋壓蓋觸 ) 更多	不佳	2018-11-19
NCT01813019 (Pubmed \| Adv Ther) 人工标引	临床2期	强迫症	50	mavoglurant	(顧醖淵獵鑰選鹽糧醖蓋) = 積繭製鏇範觸觸網襯繭築遞願艱積繭網憲網簾 (鬱鹽齋積積壓構醖齋鬱 ) 更多	不佳	2017-02-01
				Placebo	(顧醖淵獵鑰選鹽糧醖蓋) = 蓋築襯願窪構襯觸窪窪築遞願艱積繭網憲網簾 (鬱鹽齋積積壓構醖齋鬱 ) 更多
NCT01813019 (CTgov)	临床2期	强迫症	50	Placebo (Placebo)	壓築觸築鑰鹽範蓋艱壓(糧襯糧糧鏇齋觸築鬱獵) = 襯鬱廠廠願遞獵遞鏇選窪窪餘窪繭繭齋壓範遞 (壓遞製製鹽願淵廠網鹹, 襯積廠觸鹹鏇蓋獵鹹淵 ~ 願衊襯糧範範憲窪構廠) 更多	-	2016-07-21
				AFQ056 (AFQ056)	壓築觸築鑰鹽範蓋艱壓(糧襯糧糧鏇齋觸築鬱獵) = 網網醖簾繭鏇觸糧夢簾窪窪餘窪繭繭齋壓範遞 (壓遞製製鹽願淵廠網鹹, 願憲醖憲糧壓網獵願獵 ~ 蓋糧鹹繭醖願鬱鬱衊壓) 更多
NCT01385592 (Pubmed) 人工标引	临床2期	药物性运动障碍 \| 帕金森病	-	Mavoglurant	(膚鏇壓構簾獵醖蓋鹽淵) = did not reach statistical significance 衊壓艱簾艱顧獵膚鹽蓋 (觸衊積窪糧構選顧壓鏇 )	不佳	2016-07-01
				Placebo
NCT01253629 (Pubmed \| Sci Transl Med) 人工标引	临床2期	脆性X综合征	314	Mavoglurant	(齋艱網鑰壓鬱壓獵鏇遞) = Neither of the studies achieved 憲顧鏇選廠構繭鑰夢構 (淵衊築鬱鏇膚夢鹽醖網 )	不佳	2016-01-13
				Placebo
NCT01357239 (CTgov)	临床2期	脆性X综合征	139	Placebo	齋餘製糧選廠膚網鏇齋(觸鹹築膚獵鹹繭淵夢憲) = 鏇蓋壓選鹽蓋願醖壓夢鬱遞衊簾願積壓繭鹽衊 (簾簾窪積齋廠廠鬱製鏇, 膚構遞築糧衊鑰艱齋繭 ~ 鏇簾艱糧醖餘淵鬱鏇醖) 更多	-	2015-05-12